To appraise the clinical and cost effectiveness of fremanezumab within its marketing authorisation for preventing migraine.
Status In progress
Process STA pre-2018
ID number 1368

Provisional Schedule

Expected publication 15 April 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG)


Companies sponsors Teva Pharmaceuticals (fremanezumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Migraine Trust
Professional groups Association of British Neurologists
  British Association for the Study of Headache
  Royal College of Physicians
  UK Clinical Pharmacy Association


Comparator companies Novartis Pharmaceuticals (erenumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
12 March 2020 - 26 March 2020 Final appraisal document
06 February 2020 Committee meeting: 2
20 December 2019 The company, Teva, have asked to submit additional analyses with their response to the appraisal consultation, and this request has been accepted. To allow a review of the evidence, the second appraisal committee meeting has been moved to 6 February 2020.
15 November 2019 - 06 December 2019 Appraisal consultation
22 October 2019 Committee meeting: 1
15 January 2019 The company (Teva) has requested additional time to prepare its submission for fremanezumab. As a consequence, the first committee meeting discussion has been rescheduled and will now take place on 22 October 2019.
24 October 2018 In progress, Invitation to participate
24 October 2018 Invitation to participate
04 April 2018 - 02 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance